Abstract: The present invention is directed to a method for the diagnosis of cancer involving the plasma membrane citrate transporter (pmCiC). The invention is further directed to a modified substrate or modulator of pmCiC, the use of pmCiC as a tumor marker and a method of screening for a modulator of pmCiC activity.

Abstract: 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

Abstract: 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

Abstract: Anti-human interleukin 3 (IL-3) antibodies or fragments thereof according to the present invention are useful as therapeutic agents. The antibodies can be used in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated expression or levels of human IL-3 in a patient, especially inflammatory or autoimmune diseases, such as rheumatoid arthritis. The antibodies can also be used to detect human IL-3 expressed by human cells.

Abstract: The present invention is directed to a method for the diagnosis of cancer involving the plasma membrane citrate transporter (pmCiC). The invention is further directed to a modified substrate or modulator of pmCiC, the use of pmCiC as a tumor marker and a method of screening for a modulator of pmCiC activity.

Abstract: A photosensitizer-containing dispersion, and use thereof.

Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: Novel anti-interleukin 3 (IL-3) antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN (SEQ ID NO: 2). The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis.

Abstract: For determining the presence and amount of human interleukin 3 (IL-3) in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3-antibody, fragment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necessary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.

Abstract: For determining the presence and amount of human IL-3 in a sample, the present invention provides a diagnostic method, wherein an anti-IL-3- antibody, fr agment or construct thereof is added to said sample under conditions which allow for binding said antibody, fragment or construct thereof to IL-3 and detecting the amount of antibody bound IL-3 in said sample, wherein the anti-IL-3-antibody is clone 13. Further subject matter of the present invention are the novel antibody clone 13, a nucleic acid encoding said antibody and a hybridoma cell line which produces antibody clone 13. A diagnostic assay kit contains all necesary reagents and materials for performing such assay, preferably an ELISA assay and especially preferably contains antibody clones 13 and 11.